TICKERNERD
Menu
SVRASVRAHealthcare · Biotechnology

SVRA Stock Forecast: Savara, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$4.82
−2.63% on the day

The 9 Wall Street analysts covering Savara, Inc. hold a median 12-month price target of $11 — +117.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 39 of 100 as at 31 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$987.7M
Ticker Nerd rank
39/ 100
Median analyst target
$11
Analysts covering
9
Revenue$0.0
Operating income−$41.0M
Net income−$40.2M
Free cash flow−$30.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+14.2%
1M
−6.6%
YTD
−20.1%
1Y
+12.1%
From 52W high
−30.5%
From 52W low
+22.0%
$3.95
$6.94
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SVRA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Savara, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
39/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
76
Momentum
71
Accruals
67
Value
57
Size
44
Revisions
39
Growth
34
Quality
31
Issuance
26

Volatility (76): The share price has been relatively steady.

Issuance (26): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SVRA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SVRA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4.00$6.00$8.00$10.00$12.00$14.00$16.00Jan 26Apr 26Jul 26Oct 26SVRAHigh $16Median $11Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $9Median $11High $16

The green dot is the last close — the median target sits +117.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Oct 2026JP MorganInitiatesOverweight$12
23 Dec 2025HC Wainwright & Co.MaintainsBuy—
23 Dec 2025HC Wainwright & Co.MaintainsBuy$8.00 → $10
18 Dec 2025Wells FargoMaintainsOverweight—
18 Dec 2025Wells FargoMaintainsOverweight$7.00 → $9.00
14 Nov 2025OppenheimerMaintainsOutperform—
13 Nov 2025CitizensMaintainsMarket Outperform—
23 Oct 2025JMP SecuritiesMaintainsMarket Outperform—
9 Sept 2025GuggenheimMaintainsBuy—
8 Sept 2025OppenheimerMaintainsOutperform—
3 Sept 2025HC Wainwright & Co.MaintainsBuy—
15 Aug 2025HC Wainwright & Co.UpgradeBuy—
15 Aug 2025OppenheimerMaintainsOutperform—
1 June 2025OppenheimerMaintainsOutperform—
29 May 2025HC Wainwright & Co.DowngradeNeutral—
28 May 2025Evercore ISI GroupMaintainsIn-Line—
28 May 2025GuggenheimMaintainsBuy—
28 May 2025Wells FargoMaintainsOverweight—
31 Mar 2025Evercore ISI GroupMaintainsHold—
28 Mar 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

SVRA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SVRA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Savara, Inc. returned +12.1% against +12.4% for the S&P 500, dividends included.

SVRA vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160Jan 26Apr 26Jul 26Oct 26SVRAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SVRA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
4
Fundamentals

Savara, Inc. (SVRA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−9.1×

Cheaper than 93% of US stocks

Price / sales
—
Price / book
8.5×

Cheaper than 10% of US stocks

EV / EBITDA
−7.6×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−105.5%

Higher than 13% of US stocks

Return on assets
−50.1%

Higher than 8% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Savara, Inc. (SVRA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Savara, Inc. has a market value of $987.7M and an enterprise value of $1.1B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$139.3M.

  • Free cash flow in the twelve months to 30 June 2026: −$110.7M.

  • Savara, Inc. spent $5.1M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 205.4M.

  • Trailing P/E: −9.1×; forward P/E: −13.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Savara, Inc. employs 70 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 1 Nov 2026

Data provided by Twelve Data

Peers

SVRA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SVRASavara, Inc.$987.7M39
RIGLRigel Pharmaceuticals, Inc.$949.3M89
ORICOric Pharmaceuticals, Inc.$956.5M48
CGEMCullinan Therapeutics, Inc.$923.7M72
ODTXOdyssey Therapeutics, Inc.$921.8M0
OBXObsidian Therapeutics, Inc.$912.9M62
KURAKura Oncology, Inc.$910.7M75

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Savara, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SVRA news & analysis

Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment

Business Wire · 21 Oct 2026positive

Savara presented a poster at the CHEST 2026 Annual Meeting reporting a post-hoc analysis of the IMPALA trial. The analysis evaluated molgramostim’s effects in aPAP patients with mildly decreased or normal baseline diffusion capacity.

Why it matters — The presentation adds analysis of molgramostim treatment effects in a subgroup of aPAP patients with mild or no diffusion impairment.

Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026

Business Wire · 12 Oct 2026positive

Savara announced that CHEST 2026 accepted an encore oral presentation of Phase 3 IMPALA-2 data and a poster presentation of Phase 2/3 IMPALA data. The meeting is scheduled for October 18–21 in Phoenix, Arizona.

Why it matters — The presentations will feature clinical-trial data on molgramostim for autoimmune pulmonary alveolar proteinosis, a program relevant to Savara watchers.

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026

Business Wire · 24 Aug 2026positive

Savara announced that one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial of molgramostim inhalation solution in autoimmune pulmonary alveolar proteinosis were accepted for the European Respiratory Society Congress in Barcelona, September 5-9, 2026. The data show molgramostim continues to improve lung function, exercise capacity, and quality of life while reducing disease biomarkers.

Why it matters — SVRA watchers would care because these accepted presentations highlight continued positive efficacy data from the lead molgramostim Phase 3 program in a rare respiratory disease.

Savara Announces New Employment Inducement Grant

Business Wire · 20 Aug 2026neutral

Savara announced that its Compensation Committee granted inducement awards consisting of stock options and restricted stock units to eight new employees joining the company.

Why it matters — The grant provides insight into how Savara is using equity incentives to attract and retain new hires, though it may also introduce modest dilution for existing shareholders.

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

Business Wire · 11 Aug 2026neutral

Savara Inc. reported its financial results for the second quarter ending June 30, 2026, and provided a business update. The company noted that regulatory applications are under review across the U.S., EU, and U.K., with the U.S. representing its nearest-term opportunity.

Why it matters — SVRA watchers would care because the report updates the company's financial position and highlights the status of regulatory applications that are central to its near-term prospects.

FAQ

Frequently asked questions about SVRA stock

What is the SVRA stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Savara, Inc. have a median 12-month price target of $11, with estimates ranging from $9 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SVRA stock a buy right now?

Of the 9 analysts covering Savara, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Savara, Inc. 39 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SVRA?

As at 31 Oct 2026, Savara, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (76 of 100).

Will SVRA stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +117.8% from the last close, and Ticker Nerd's factor model ranks Savara, Inc. 39 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SVRA stock forecast for 2030?

No analyst covering Savara, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SVRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $16 over the next 12 months.

How has SVRA stock performed over the past year?

Savara, Inc. returned +12.1% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Savara, Inc. do?

Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases.

What is the latest news on SVRA?

The most recent item we track (Business Wire, 21 Oct 2026): "Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment". Savara presented a poster at the CHEST 2026 Annual Meeting reporting a post-hoc analysis of the IMPALA trial. The analysis evaluated molgramostim’s effects in aPAP patients with mildly decreased or normal baseline diffusion capacity.

Company

About Savara, Inc.

Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. The company’s work centers on developing inhaled therapies designed to address serious lung disorders with limited treatment options, with a particular emphasis on autoimmune pulmonary alveolar proteinosis. Its lead product candidate, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor being advanced through late-stage clinical development. Savara’s current business is concentrated on research, clinical development, and regulatory progress in orphan and specialty respiratory medicine, rather than on a broad commercial product portfolio. The company serves a niche market within biotechnology and pharmaceuticals, where expertise in pulmonary medicine and rare disease development is central to its role.

CEO Mr. Matthew Pauls J.D., M.B.A. · 70 employees · United States · https://www.savarapharma.com